A K562 Cells Were Treated With Or Without Control 10 Nm Acm 2 M

(A) K562 cells were treated with or without (control) 10 nM ACM, 2 µM ...
(A) K562 cells were treated with or without (control) 10 nM ACM, 2 µM ...
(A) Cells were treated with or without ACM (5, 10, 15 or 20 nM) for 24 ...
(A) Cells were treated with or without ACM (5, 10, 15 or 20 nM) for 24 ...
The K562 and K562/A02 cells were treated with PBS or PH II-7 (200 nM ...
The K562 and K562/A02 cells were treated with PBS or PH II-7 (200 nM ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
(A) V-K562 cells or B-K562 cells were treated with 100 nM PMA (+) or ...
(A) V-K562 cells or B-K562 cells were treated with 100 nM PMA (+) or ...
(A) V-K562 or B-K562 cells were treated with 100 nM PMA for the times ...
(A) V-K562 or B-K562 cells were treated with 100 nM PMA for the times ...
K562 cells with or without ME2 knockdown were lysed with RIPA lysis ...
K562 cells with or without ME2 knockdown were lysed with RIPA lysis ...
The K562 cells were incubated for 48 h without lycopene or with ...
The K562 cells were incubated for 48 h without lycopene or with ...
K562 cells nontreated or treated with imatinib or BP-1-108 were fixed ...
K562 cells nontreated or treated with imatinib or BP-1-108 were fixed ...
(A–D) K562 cells were treated with 200 nM of indicated aptamer chimeras ...
(A–D) K562 cells were treated with 200 nM of indicated aptamer chimeras ...
Jurkat and K562 cell lines were untreated or treated with Tg (0.1, 0.5 ...
Jurkat and K562 cell lines were untreated or treated with Tg (0.1, 0.5 ...
45.1 Jurkat and K562 cells were untreated, treated with 50 μM CQ ...
45.1 Jurkat and K562 cells were untreated, treated with 50 μM CQ ...
A, cell viability assay of K562 or PBM cells treated with 1, 3 and 5 mM ...
A, cell viability assay of K562 or PBM cells treated with 1, 3 and 5 mM ...
Cell cycle distribution of K562 cells with or without Stel B treatment ...
Cell cycle distribution of K562 cells with or without Stel B treatment ...
(A) K562 cells were treated with the indicated concentrations of human ...
(A) K562 cells were treated with the indicated concentrations of human ...
K562 cells were treated with increasing concentrations of tyrosine ...
K562 cells were treated with increasing concentrations of tyrosine ...
(A) Activity western blot of K562 cells. Cells were treated with ...
(A) Activity western blot of K562 cells. Cells were treated with ...
(A) K562 cells were treated with imatinib with 1µM for 24 hr and the ...
(A) K562 cells were treated with imatinib with 1µM for 24 hr and the ...
Jurkat (A) and K562 (B) cells were untreated (control) or treated 80nM ...
Jurkat (A) and K562 (B) cells were untreated (control) or treated 80nM ...
Confocal microscopic images of K562 cells treated with smaller (avg ...
Confocal microscopic images of K562 cells treated with smaller (avg ...
Cell survival of transfected K562 cells treated with OA. (a) K562 cells ...
Cell survival of transfected K562 cells treated with OA. (a) K562 cells ...
ALCAM promotes apoptosis of K562 cells treated with PMA | Open-i
ALCAM promotes apoptosis of K562 cells treated with PMA | Open-i
(A) Confocal images of K562 and K562/VCR cells treated with KNf-pV ...
(A) Confocal images of K562 and K562/VCR cells treated with KNf-pV ...
Cell viability of K562 cells treated with different concentrations of ...
Cell viability of K562 cells treated with different concentrations of ...
(A) Confocal images of K562 and K562/VCR cells treated with KNf-pV ...
(A) Confocal images of K562 and K562/VCR cells treated with KNf-pV ...
Cytotoxicity of treated or non-treated NK cells towards K562 cell at ...
Cytotoxicity of treated or non-treated NK cells towards K562 cell at ...
Megakaryocytes produced pro-survival exosomes. K562 cells were treated ...
Megakaryocytes produced pro-survival exosomes. K562 cells were treated ...
Cytotoxicity of treated or non-treated NK cells towards K562 cell at ...
Cytotoxicity of treated or non-treated NK cells towards K562 cell at ...
Cell viability of K562 cells treated with different concentrations of ...
Cell viability of K562 cells treated with different concentrations of ...
Cell cycle analysis of K562 cells treated with Br-Ell-SO3Na. (A ...
Cell cycle analysis of K562 cells treated with Br-Ell-SO3Na. (A ...
(A) K562 cells cultured in glucose-free culture medium were treated ...
(A) K562 cells cultured in glucose-free culture medium were treated ...
Electron microscopy images of K562 cells. A control cell without ...
Electron microscopy images of K562 cells. A control cell without ...
(A) K562 cells were treated as indicated for different time periods and ...
(A) K562 cells were treated as indicated for different time periods and ...
Electron microscopy images of K562 cells. A control cell without ...
Electron microscopy images of K562 cells. A control cell without ...
(a) K562 cells were co-cultured with stromal cells in the presence of ...
(a) K562 cells were co-cultured with stromal cells in the presence of ...
(A) K562 cells were pre-treated with different doses of CsA for 6 h ...
(A) K562 cells were pre-treated with different doses of CsA for 6 h ...

Loading image details...

Source
Dimensions